Cargando…

Development of antibody arrays for monoclonal antibody Higher Order Structure analysis

Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xing, Li, Qing, Davies, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748713/
https://www.ncbi.nlm.nih.gov/pubmed/23970865
http://dx.doi.org/10.3389/fphar.2013.00103
_version_ 1782281117472129024
author Wang, Xing
Li, Qing
Davies, Michael
author_facet Wang, Xing
Li, Qing
Davies, Michael
author_sort Wang, Xing
collection PubMed
description Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of the peptides to a carrier protein, KLH. It was shown that good peptide specificity was achieved from the antibodies generated. Using more than 30 different polyclonal antibodies to measure the surface epitope distribution, it was shown that the mAb antibody array can detect epitope exposure as low as 0.1% of defined mAb populations. This ELISA-based analysis of mAb epitope exposure can be considered as a measurement of “conformational impurity” in biologics development, similar to the analysis of other product-related impurities such as different forms of glycosylation, deamidation, and oxidation. This analysis of “conformational impurity” could provide valuable information on the mAb conformational comparability for biosimilar mAbs as well as novel mAbs, especially in the area of protein immunogenicity. Furthermore, stability studies indicated that there are several conformational “hot spots” in many mAbs tested, especially in the hinge region. This antibody array technology can be used for novel mAb Higher Order Structure (HOS) analysis during process and formulation development. Another important area of application is for biosimilar mAb development where the innovator molecule and biosimilar molecule could be compared based on their systemic “fingerprint” from the 30 plus antibodies.
format Online
Article
Text
id pubmed-3748713
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-37487132013-08-22 Development of antibody arrays for monoclonal antibody Higher Order Structure analysis Wang, Xing Li, Qing Davies, Michael Front Pharmacol Pharmacology Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of the peptides to a carrier protein, KLH. It was shown that good peptide specificity was achieved from the antibodies generated. Using more than 30 different polyclonal antibodies to measure the surface epitope distribution, it was shown that the mAb antibody array can detect epitope exposure as low as 0.1% of defined mAb populations. This ELISA-based analysis of mAb epitope exposure can be considered as a measurement of “conformational impurity” in biologics development, similar to the analysis of other product-related impurities such as different forms of glycosylation, deamidation, and oxidation. This analysis of “conformational impurity” could provide valuable information on the mAb conformational comparability for biosimilar mAbs as well as novel mAbs, especially in the area of protein immunogenicity. Furthermore, stability studies indicated that there are several conformational “hot spots” in many mAbs tested, especially in the hinge region. This antibody array technology can be used for novel mAb Higher Order Structure (HOS) analysis during process and formulation development. Another important area of application is for biosimilar mAb development where the innovator molecule and biosimilar molecule could be compared based on their systemic “fingerprint” from the 30 plus antibodies. Frontiers Media S.A. 2013-08-21 /pmc/articles/PMC3748713/ /pubmed/23970865 http://dx.doi.org/10.3389/fphar.2013.00103 Text en Copyright © 2013 Wang, Li and Davies. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Xing
Li, Qing
Davies, Michael
Development of antibody arrays for monoclonal antibody Higher Order Structure analysis
title Development of antibody arrays for monoclonal antibody Higher Order Structure analysis
title_full Development of antibody arrays for monoclonal antibody Higher Order Structure analysis
title_fullStr Development of antibody arrays for monoclonal antibody Higher Order Structure analysis
title_full_unstemmed Development of antibody arrays for monoclonal antibody Higher Order Structure analysis
title_short Development of antibody arrays for monoclonal antibody Higher Order Structure analysis
title_sort development of antibody arrays for monoclonal antibody higher order structure analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748713/
https://www.ncbi.nlm.nih.gov/pubmed/23970865
http://dx.doi.org/10.3389/fphar.2013.00103
work_keys_str_mv AT wangxing developmentofantibodyarraysformonoclonalantibodyhigherorderstructureanalysis
AT liqing developmentofantibodyarraysformonoclonalantibodyhigherorderstructureanalysis
AT daviesmichael developmentofantibodyarraysformonoclonalantibodyhigherorderstructureanalysis